Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is so tempting right now to sell other positions and place them here. Good to diversify, but if I see another dip then I may take out some more.
Yup, I don’t see this taking a plunge downwards.
Maybe in December, but what about after? There’s a better future for this company no matter what.
We’ll probably see some end of day profit taking. I’ll be surprised if it closes above .05
That’s just fine though! Because RSI is looking mighty nice for a second run.
Knock knock, it’s USRM!
On our way. Some passengers want to get off before we get there. Let em out so the rest of us can carry on!
RSI COOLED BACK DOWN and we are still in a good spot.
Yes, and the higher that RSI creeps - the more selling I’d expect for the short term folks.
For the long folks it’s just more higher highs and higher lows!
Breaking past .01 would bode very well. Break and hold over .01 and we see many good things ahead!
.0399 here. 4’s to knock down next?
That’s not a factual statement, particularly with the amount of states which have legalized medical and recreational MJ. Cannabis use and arrests are down across the nation in a major way.
Stem cell treatment will rise similarly.
Same here. Bought most of these in the 9’s because I’m confident in the team efforts here.
It may have taken years, but at least Marco got the company trading again. Pretty good for an ex-dead ‘grey market’ stock.
This company set the trend in 2014. One of the heaviest contending companies to sell grow equipment.
I’d like to see some updates from management if they will pursue top spot on equipment sales, or if they’re seeking a different revenue stream in the MJ industry as their primary focus.
Profitable stem cell company for .03 cents a share is chump change.
Work smarter, live longer - USRM.
USRM response to FDA guidelines is hitting major news sources!
My trading platform finally picked up on news that bodes well for USRM. Here it comes.
In reality, it’s amazing this stock is trading at all - much more amazing is the levels of attention Growlife is receiving.
Whether you’re for or against a resurgence, this company is on the up and up.
USRM announces they’re ready to put the nail in the RMAT coffin and get things going on an even LARGER scale of commercialization.
Of course shorts are scared. Time to put on the big boy pants and go long.
Time to shine TRTC. As one of the few companies that kept a fraction of their value from the 2014 bust, TRTC is well primed for some upside after trading these ranges for years.
Breaking into .01 today would be huge!
But can it get there and stay there? Serious confidence if it can.
Holding a company in the OTC which is fully reporting is good.
Holding one that has positive year over year results is better, and rare.
I look forward to when we can say we also hold a company that was able to capitalize fully on an emerging sector.
Waiting on management. Stakes are high on their next move.
Every new industry takes some time to get into the limelight.
Just like the now MULTI BILLION DOLLAR MJ industry, they had and continue to have setbacks. Stem cell tech is similar. A treatment that has been around for a while, and suffered much controversy through numerous bad actors. Not to mention the previous moral issue of using fetal tissue which has now been circumvented.
People seek out these treatments on a decent volume as of now, but when the government places guidelines then people will be FLOODING out the woodwork. Stem Cel Treatments excel Particularly in a culture where work harder and live longer are the strongest creeds.
I’m sure long holders are feeling stir crazy hanging out in the high 2’s this long - particularly after recent surges pointing that this will blast through 3’s. This company is just as set to capitalize on a multi-billion dollar industry and is one of the few OTC companies I’d ever consider holding long term. Increasing earnings, breakthrough treatments, and some upcoming decisions to be made by the government.
Cheer up folks. It’s like watching paint dry right now, but that paint is going to dry to a beautiful color.
Let it run! Let it run! Let it run!
On the plus side, Sessions got grilled INTENSELY on his MJ stance this morning. The man didn’t have a leg to stand on.
Yup, here comes another low volume shakedown.
R/S traditionally is a leading cause of value loss. Usually you see a run up in price prior to the r/s, and a deep swing down right after - sometimes even below the original pre-r/s price.
I’d be surprised if they go through with one. No investor wants to hold through such a thing.
Yup, will be getting back into trtc in the next month or so. They’re one of the few legit MJ companies out there with a good fallback if needed.
They’ve been trading sideways for what feels like years now. Just hanging out in the low teens-mid twenties.
I’m sure many of us remember this rocketing to... 1.40 was it? Back in 2014. Trtc would have to screw up pretty hardcore to stop themselves from being worth a few dollars in the next few years.
Yes, and my hope is that they have a backup plan to deal with any issues in obtaining RMAT designation.
Their previous endeavor had them back and forth with the FDA until placing RMAT on the back-burner.
But what happens to the company if the same thing happens after guidelines? They go through some similar song and dance with the FDA only to find the process stalled or not worth pursuing?
I’m hopeful that such a catalyst as RMAT will be taken advantage of here, but I? want to know what else USRM could benefit from as an impending catalyst. The world is primed to openly accept stem cell procedures, surely RMAT isn’t their only avenue for a big leg up.
In 2014, they sat and consolidated between .04 and .06 for what felt like forever. Then, they started making progress, inking deals. All of a sudden, my measly share count was worth a lot.
I’m excited to see a resurgence here, but we can’t bank on nostalgia. We have to bank on competence and new deals - things I? hope to see coming soon.
Gives some perspective When you consider their downfall wasn’t directly a fault of their own, but manipulators on the outside. When they were hot in the industry, .20-.30 was a valid price point for them.
Then again you have all these outstanding shares. Makes you wonder what they’ll do to get to the front of the pack again.
Perfect, was looking for an entry
Get above .03 and stay above .03!
Yah, trouble staying above .03. Anyone want to clue me in on what’s going on?
Took my eyes off the market for a whole hour and what do I? come back to? Glorious green.
I’ll try to take my eyes off a lot more!
I? remember, I? was there. It is true that outsiders were arrested for stock manipulation. One of those guys ran his scheme on these boards - hotstockace of the money runners.
Looking forward to having some powder to place down here once again.
Yes, patience and the ability to see past the day to day - to weather the red storm so to speak.
One of my old picks did something similar in 2014. It traded between .03 - .06 for many months. One day, company made a breakthrough and shot up over .70 within a couple months. I? only had a few thousand in it at the time, but no complaints. .05 to .70 was a heck of a ride!
My autocorrect is peachy today. Deduce is apparently not a word.
But yes LOL, we could deduce that USRM and the FDA aren’t at odds anymore. We’d be reading about more problems if they were.
curious about this one. Does the FDA have a duty to publicly announce when a company has been cleared?
Their warning gave USRM a 15 day window for response and compliance, and the response was extremely prompt - more so than we see from the company as far as news releases.
So the deadline is long gone for months now, and with no punitive actions taken by the FDA, one could appropriately seduce that everything is back on track. Which leads to the next question, what reasons would the FDA have to not approve RMAT? Last update we had was that the FDA asked for more information, and nothing of a denial.
I? had understood dilution was either at an end or near the end. Do you have any additional information, or are these rumors?
I? can stomach some dilution to find certain advanced, but I?’d like to find out the scope to decide if these are reasonable concessions or if they’re taking advantage.
A few reasons. Triggering stop losses, lowering value in order to amass more shares at a cheaper price. There are also short interests, which are those who seek to profit from the stock declining in value.
The more savvy folks know how to time a good short and a good hold. I’ve never shorted something, but I? understand it works well when you have a safe bet that a stock will drop. Say you saw the news article that SNAP lost millions on some silly camera glasses they made, then you may be inclined to short that stock.
Likewise, when USRM announced they were suspending the pursuit of RMAT, someone deciding to short from .17 to .02 stood to make a lot of money. It’s all a risk, because you would also be betting the company wouldn’t recover quickly.
Yup, but this isn’t a traditional buy the hype, sell the news since no one could have called great earnings.
It was more of a knockdown on positive future. It’s impressive how hard these MM’s will push just to get the price down a few fractions of a cent. It’s indicative of those wanting in cheaper to ride it on up. To those who aren’t adding anymore, it’s annoying. To those who want to scoop cheap shares, it’s a gift.
Tomas has done what he said he would, focus on business while they have RMAT aspirations on the back burner. This is eventually .08 to .10 without RMAT hype, and we’ve already seen it get near .20 when that gets going again. To sustain long term levels, the company needs to hinge on more than just RMAT as a catalyst. The market is still punishing this company for their failure to achieve on first attempt.
This is true. Whenever I see a dip, I check the volume. On a dip with under 1 mil in volume for the first half of the day, it’s no biggie. Accumulators are looking for cheaper shares, and getting the prices they want.
It would be different if we had 5 mil in trades and this dip, but this stock traditionally sees gains on high volume and dips on low volume. Good sign IMO. Expect these games to go on a bit longer while bigger holders seek lower prices.
Most of our good news days see a dip in the short term which gets followed up with Green Days shortly after.
It helps when positive news is picked up by all platforms or heavily advertised.
I’m 50/50 on the way they’ve made releases. On one hand, the company is a diamond in the rough. It takes some digging and attention to learn about the positives here.
On the other hand, if they could muscle some coverage about their earnings and expansion plans, we might see short term gains sooner. Their updates are great confidence boosters for those already holding, however if they reach more of the public - then you get new stakeholders coming in.